Clinical Trial Update: Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% [Phase 3]

View source ↗

Summary

Phase 3 trial update for ProMetic BioTherapeutics' intravenous immunoglobulin (10%) in primary immunodeficiency has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% (intravenous immunoglobulin)

Snippet

Sponsor: Prometic Biotherapeutics, Inc. | Conditions: Primary Immunodeficiency | Phase 3 | Status: COMPLETED | Results posted: 2021-08-20